Device and filter cartridge for separating plasma from whole blood
    2.
    发明授权
    Device and filter cartridge for separating plasma from whole blood 有权
    用于从血液中分离血浆的装置和滤芯

    公开(公告)号:US09283313B2

    公开(公告)日:2016-03-15

    申请号:US14615743

    申请日:2015-02-06

    发明人: Herfried Huemer

    摘要: A multi-part device for separating plasma from whole blood is provided, with a sample taking unit for receiving whole blood, a filter unit with a layered filter with multiple layers for extracting plasma, and a pumping unit, typically a plunger pump, for creating a partial vacuum in the filter unit. The filter unit and a plasma collector vessel with a conical tip extending towards the filter unit are contained in a filter cartridge, which may be taken apart after plasma extraction, thus exposing the conical tip of the plasma collector vessel for sample input into an analyzer.

    摘要翻译: 提供了用于从全血中分离血浆的多部分装置,具有用于接收全血的取样单元,具有用于提取等离子体的多层的分层过滤器的过滤单元,以及通常为柱塞泵的抽吸单元,用于产生 过滤器单元中的部分真空。 过滤器单元和具有朝向过滤器单元延伸的锥形末端的等离子体收集器容纳在过滤器滤芯中,其可以在等离子体提取之后被分离,从而将用于样品输入的等离子体收集器容器的锥形尖端暴露于分析器中。

    Methods of isolating blood components using a microcentrifuge and uses thereof
    3.
    发明申请
    Methods of isolating blood components using a microcentrifuge and uses thereof 有权
    使用微量离心机分离血液成分的方法及其用途

    公开(公告)号:US20020182664A1

    公开(公告)日:2002-12-05

    申请号:US10116729

    申请日:2002-04-04

    摘要: Methods and apparatuses for the separation a predetermined cellular component from a bodily fluid or tissue by centrifugation are provided. More specifically, this invention provides a method for the separation and isolation of one or more components, such as stem cells, buffy coat, bone marrow cells, erythrocytes, leukocytes, thrombocytes, serum, fluorescently labeled cells, and magnetically labeled cells, from whole blood, bone marrow, buffy coat, fat tissue, muscle tissue, and nerve tissue by centrifugation, wherein the components are isolated while the centrifuge is rotating.

    摘要翻译: 提供了通过离心从体液或组织分离预定的细胞组分的方法和装置。 更具体地说,本发明提供了从整体分离和分离一种或多种组分如干细胞,血沉棕黄层,骨髓细胞,红细胞,白细胞,血小板,血清,荧光标记细胞和磁性标记细胞的方法 血液,骨髓,血沉棕黄层,脂肪组织,肌肉组织和神经组织,其中在离心机旋转时分离组分。

    Irradiation of blood products
    7.
    发明授权
    Irradiation of blood products 失效
    血液制品的照射

    公开(公告)号:US4726949A

    公开(公告)日:1988-02-23

    申请号:US900217

    申请日:1986-08-26

    IPC分类号: A61K35/14 A61M1/36

    CPC分类号: A61M1/3681 A61M1/3616

    摘要: A thin film of white blood cells is irradiated with ultraviolet radiation predominately of a wavelength of 280 to 320 nanometers, and preferably at an intensity of 4 to 15 milliwatts per square cm. At such a radiation intensity it is not necessary to agitate the thin film of white blood cells to accomplish the purposes of this invention. The white blood cells so processed substantially lose their capability to set off an immune reaction in an alloimmunized patient. The white blood cells may preferably be placed into such film in a flat, flexible bag made of poly(ethylene-vinyl acetate) plastic, with the flat, flexible bag being stretched in a direction normal to the path of ultraviolet radiation.

    摘要翻译: 用紫外线辐射主要为280〜320nm的波长的白细胞的薄膜,优选为4〜15毫瓦每平方厘米的强度。 在这样的辐射强度下,不需要搅动白细胞的薄膜来实现本发明的目的。 如此处理的白细胞基本上丧失了在同种异体免疫的患者中引起免疫反应的能力。 白血细胞可以优选地放置在由聚(乙烯 - 乙酸乙烯酯)塑料制成的平坦柔性袋中的这种膜中,其中平的柔性袋沿着垂直于紫外线辐射的方向被拉伸。

    Method and device for treating cancer

    公开(公告)号:US09656014B2

    公开(公告)日:2017-05-23

    申请号:US14879019

    申请日:2015-10-08

    申请人: Brian J Leberthon

    发明人: Brian J Leberthon

    IPC分类号: A61M37/00 A61M1/34 A61M1/36

    摘要: A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.